Live Breaking News & Updates on Novartis division

Stay informed with the latest breaking news from Novartis division on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Novartis division and stay connected to the pulse of your community

USFDA gives nod to Novartis' therapy for rare cancer among children - Pharma News

USFDA gives nod to Novartis' therapy for rare cancer among children - Pharma News
financialexpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialexpress.com Daily Mail and Mail on Sunday newspapers.

United-states , Philadelphia , Pennsylvania , India , Tina-deignan , Theodore-laetsch , Sun-pharma , Drug-administration , Dr-reddy-labs , Developmental-therapeutics-program , Novartis , Therapeutic-area-head

Effect of combination treatment with glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors on incidence of cardiovascular and serious renal events: population based cohort study

Objective To determine whether the combined use of glucagon-like peptide-1 (GLP-1) receptor agonists and sodium-glucose cotransporter-2 (SGLT-2) inhibitors is associated with a decreased risk of major adverse cardiovascular events and serious renal events compared with either drug class alone among patients with type 2 diabetes, and to assess the effect of the combination on the individual components of major adverse cardiovascular events, heart failure, and all cause mortality.

Design Population based cohort study using a prevalent new-user design, emulating a trial.

Setting UK Clinical Practice Research Datalink linked to Hospital Episode Statistics Admitted Patient Care and Office for National Statistics databases.

Participants Two prevalent new-user cohorts were assembled between January 2013 and December 2020, with follow-up until the end of March 2021. The first cohort included 6696 patients who started GLP-1 receptor agonists and added on SGLT-2 inhibitors, and the second included 8942 patients who started SGLT-2 inhibitors and added on GLP-1 receptor agonists. Combination users were matched, in a 1:1 ratio, to patients prescribed the same background drug, duration of background drug, and time conditional propensity score.

Main outcome measures Cox proportional hazards models were fitted to estimate the hazard ratios and 95% confidence intervals of major adverse cardiovascular events and serious renal events, separately, comparing the GLP-1 receptor agonist-SGLT-2 inhibitor combination with the background drug, either GLP-1 receptor agonists or SGLT-2 inhibitors, depending on the cohort. Secondary outcomes included associations with the individual components of major adverse cardiovascular events (myocardial infarction, ischaemic stroke, cardiovascular mortality), heart failure, and all cause mortality.

Results Compared with GLP-1 receptor agonists, the SGLT-2 inhibitor-GLP-1 receptor agonist combination was associated with a 30% lower risk of major adverse cardiovascular events (7.0 v 10.3 events per 1000 person years; hazard ratio 0.70, 95% confidence interval 0.49 to 0.99) and a 57% lower risk of serious renal events (2.0 v 4.6 events per 1000 person years; hazard ratio 0.43, 0.23 to 0.80). Compared with SGLT-2 inhibitors, the GLP-1 receptor agonist-SGLT-2 inhibitor combination was associated with a 29% lower risk of major adverse cardiovascular events (7.6 v 10.7 events per 1000 person years; hazard ratio 0.71, 0.52 to 0.98), whereas serious renal events generated a wide confidence interval (1.4 v 2.0 events per 1000 person years; hazard ratio 0.67, 0.32 to 1.41). Secondary outcomes generated similar results but with wider confidence intervals.

Conclusions In this cohort study, the GLP-1 receptor agonist-SGLT-2 inhibitor combination was associated with a lower risk of major adverse cardiovascular events and serious renal events compared with either drug class alone.

This study is based on data from the Clinical Practice Research Datalink obtained under license from the UK Medicines and Healthcare products Regulatory Agency. The data are provided by patients and collected by the UK National Health Service as part of their care and support. The interpretation and conclusions contained in this study are those of the authors alone. Because electronic health records are classified as “sensitive data” by the UK Data Protection Act, information governance restrictions (to protect patient confidentiality) prevent data sharing via public deposition. Data are available with approval, through the individual constituent entities controlling access to the data. Specifically, the primary care data can be requested via application to the Clinical Practice Research Datalink (<https://www.cprd.com>).

United-kingdom , Bristol , City-of , Montreal , Quebec , Canada , Canadian , British , Canadian-institutes-of-health-research , Novartis , Setting-united-kingdom-clinical-practice-research-datalink

Nestle India Q1 results Net profit up nearly 27% at Rs 934.17 crore

Nestle India Q1 results Net profit up nearly 27% at Rs 934.17 crore
financialexpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialexpress.com Daily Mail and Mail on Sunday newspapers.

Petersburg , Sankt-peterburg , Russia , Hindustan , India-general- , India , Patna , Bihar , Israel , Badshah , Fars , Iran

Autologous Cell Therapy Industry Sets Sights on USD 33.1 Billion With 20.2% CAGR | Market.Us

According to a recent report by Market.us, the Global Autologous Cell Therapy Market size is expected to be worth around USD 33.1 Billion by 2032 from USD 6.6 Billion in 2023, growing at a CAGR of 20.2% during the forecast period from 2024 to 2032.The Autologous Cell Therapy Market represents a groundbreaking approa...

United-states , New-york , America , Holostem-terapie-avanzate , Bio-elpida , Immediate-delivery-available-buy-this-premium-research , Corning-inc , Regional-development-status , Lonza-group , Global-business-development-team , S-stem-cell-inc , Vericel-corporation

Why the fight against malaria is having a 'Red Queen' moment

As Alice and the Red Queen run towards a chessboard in Lewis Carroll’s childhood classic, the wind whistling in their ears, the little girl makes a curious discovery: despite running very fast for a very long time, she hasn’t actually moved.

Bangkok , Krung-thep-mahanakhon , Thailand , Azerbaijan , Nigeria , Uganda , Djibouti , Peru , Tajikistan , Belize , Eritrea , United-kingdom

Mereo BioPharma : UK Annual Report 2023 - MarketScreener

Company Number 09481161

MEREO BIOPHARMA GROUP PLC

Annual Report and Accounts

Year ended December 31, 2023

...

London , City-of , United-kingdom , United-states , Bishopsgate , United-kingdom-general- , America , Feng-biosciences , Justin-roberts , Deepa-pakianathan , Marc-yoskowitz , Pierre-jacquet

Why Big Pharma Is Following Novartis' Lead In A $25 Billion Market

Novartis paved the way for radiopharmaceuticals. Now, Big Pharma thinks it can do better — and biotech stocks have soared on a spate of deals. The post Why…

Novartis , Big-pharma , News , Ggregator , Reaking-news , Uration , Edia ,

Morphic Announces Corporate Highlights and Financial Results for the First Quarter 2024

-Enrollment continued on target in EMERALD-2 Phase 2b trial of MORF-057 in ulcerative colitis-

Simon-cooper , Chris-erdman , Praveen-tipirneni , Key-additions-to-morphic-leadership-team , Development-program , Napp-pharmaceutical-research , Exchange-commission , University-of-newcastle-upon-tyne-medical-school , Morphic-holding-inc , Wyeth-research , Human-genome-sciences , Kadmon-holdings

GlobalData : APPLAUSE-IgAN trial interim analysis highlights Novartis' potential to differentiate in IgAN space, says GlobalData

25 Apr, 2024 APPLAUSE-IgAN trial interim analysis highlights Novartis' potential to differentiate in IgAN space, says GlobalData

Share

...

Kajal-jaddoo , Novartis , World-congress , Senior-pharma-analyst , Chinook-therapeutics , Markets ,

Diabetic Kidney Disease (DKD) - Market Insight,

Dublin, April 25, 2024 (GLOBE NEWSWIRE) -- The

Germany , Spain , United-states , Japan , United-kingdom , France , Dublin , Ireland , Italy , American , Daiichi-sankyo , Inversago-pharma